NON-SMALL CELL LUNG CANCER

This phase II study tests a treatment made from a patient's own tumor-fighting immune cells (TILs) for non-small cell lung cancer. About 28 adults aged 18-70 whose cancer has not responded to standard treatments will receive their own expanded TILs. The goal is to see if this app…

This early-phase study tests two drugs—navlimetostat and pumitamig—together in people with a specific genetic form of advanced non-small cell lung cancer (MTAP-deficient). The main goal is to find a safe dose and see if the combination shrinks tumors. About 17 adults will take pa…

This study tests two experimental drugs (ABSK043 and glecirasib) together in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to see if the combination is safe and shrinks tumors. About 86 adults will take part in this open-label…

This pilot study looks at whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard sur…

This study tests a new drug (ANS014004) combined with a standard targeted therapy (EGFR-TKI) in people with advanced lung cancer that has a specific gene change (EGFR mutation). The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing…

This early-phase study tests a new drug called CS08399 in people with advanced solid tumors or lymphoma that have a missing MTAP gene. The main goals are to find a safe dose and see how the drug works in the body. About 186 adults will take part, and the study will also check if …

This study tests two drug combinations for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC). One group gets a new drug (amivantamab) plus a targeted pill (lazertinib) as their first treatment. Another group gets amivantamab plus chemotherapy after their can…

This early-stage study tests a new drug called FXB0871 in about 138 adults with advanced solid tumors, including lung and liver cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study is not yet…

This study is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) whose cancer has spread to distant parts of the body after they finished a targeted therapy called osimertinib. The study will test whether giving osimertinib together with chemo…

This study tests a new drug called SYS6010 against a standard chemotherapy (docetaxel) in people with a specific type of advanced lung cancer (non-squamous non-small cell) that no longer responds to standard treatments. About 506 adults will be randomly assigned to receive either…

This early-stage study tests a new gene-editing drug called EDB-102 in 15 adults with advanced non-small cell lung cancer that has spread to the liver and no longer responds to standard targeted therapy. The drug uses CRISPR technology to find and disable a specific cancer-causin…

This study tests whether giving patients with stage II-III non-small cell lung cancer a fecal transplant (from people who responded well to immunotherapy) can improve the effectiveness of their standard treatment. 68 participants will either receive the transplant plus chemothera…

This early-phase study tests a new daily pill, KQB368, in adults with advanced solid tumors that have specific KRAS mutations (G12S or G12C) and no standard curative options. The main goals are to find a safe dose and see if the drug can shrink tumors. About 48 participants will …

This study tests two different immunotherapy drug combinations (durvalumab with either monalizumab or oleclumab) followed by personalized radiation for people with advanced non-small cell lung cancer that has a high PD-L1 marker. The goal is to see which combination works better …

This phase 3 study tests whether a new drug (HS-20093) combined with adebrelimab works better than the standard chemo docetaxel for people with advanced or metastatic non-squamous non-small cell lung cancer that has no targetable gene changes. About 450 adults who have already re…

This study tests whether adding a special type of radiation (quad shot radiotherapy) to a drug called QL1706 (which boosts the immune system) plus standard chemotherapy can better control advanced non-small cell lung cancer. About 104 people with stage IV lung cancer that has not…

This study looks at whether adding electro-acupuncture to standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer live longer without their cancer getting worse. About 424 participants will receive either real or sham acupuncture alongside…

This study tests whether a fecal microbiota transplant (FMT) combined with the drug tislelizumab can help people with advanced non-small cell lung cancer whose disease got worse after prior immunotherapy. The goal is to restore the immune system's ability to fight cancer. The tri…

This study tests a new type of radiation therapy (Y-90 FAPI) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. The therapy targets a protein found on cancer cells to deliver radiation directly to tumors. The goal is to see if …

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (including colorectal, stomach, head and neck, and lung cancers) that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best…

This study tests whether adding a new drug (SYS6010) to the standard targeted therapy (osimertinib) before surgery helps shrink tumors more effectively in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). About 120 adults with stage II to IIIB c…

This study looks at how safe and effective a drug called adebrelimab is when combined with other treatments for people with advanced solid tumors, including lung and gastrointestinal cancers. About 300 participants will be observed in real-world settings to track side effects and…

This study tests a new medicine, PF-08634404, given alone or with chemotherapy for adults with early or locally advanced non-small cell lung cancer. The goal is to see if it helps shrink tumors before surgery or prevents cancer from returning after treatment. About 120 participan…

This early study tests whether adding the statin pitavastatin to standard chemotherapy can shrink tumors in people with advanced non-small cell lung cancer that has stopped responding to second-line treatment. Doctors will use a lab test on patient-derived tumor-like cell cluster…

This study tests whether the targeted drug divarasib can keep lung cancer from returning after surgery in people with a specific KRAS G12C gene mutation. About 400 adults with stage II-III non-small cell lung cancer who had surgery and prior chemo-immunotherapy will receive eithe…

This early-phase trial tests the safety of a new drug, IM-1617, in about 175 adults with advanced solid tumors (colorectal, lung, breast, stomach, esophageal, or other cancers that have spread or can't be removed by surgery). The study first finds a safe dose, then checks how wel…

This study tests whether adding the experimental drug plinabulin to standard chemotherapy (docetaxel) helps people with advanced non-squamous non-small cell lung cancer live longer. It includes about 442 adults whose cancer has gotten worse after immunotherapy and platinum chemo,…

This study looks at whether removing the main lung tumor before giving immunotherapy (sintilimab) and chemotherapy can help people with advanced non-small cell lung cancer live longer without the disease getting worse. About 118 adults aged 18-75 with a specific type of lung canc…

This study tests a combination of the targeted drug limertinib plus chemotherapy (carboplatin and etoposide) in people with a specific type of lung cancer (EGFR-mutant NSCLC) that has transformed into small cell lung cancer after initial targeted therapy stopped working. About 30…

This early-phase trial tests a new drug called ITC-6146RO in about 100 adults with advanced or metastatic cancers (prostate, lung, breast, or other solid tumors) that have stopped responding to standard therapies. The study has two parts: first, finding a safe dose, then checking…

This study is for people with advanced non-small cell lung cancer that has a specific change called HER2 (mutation, amplification, or overexpression) and has gotten worse after at least one prior treatment. Participants will receive two drugs, SHR-A1811 and pertuzumab, to see if …

This study is testing a new drug called SYS6090, given together with chemotherapy or other targeted drugs, for people with advanced lung cancer that cannot be removed by surgery. The goal is to find safe doses and see if the combination can shrink tumors. About 596 adults aged 18…

This study tests a new drug called AK112 in people with a specific type of lung cancer (non-squamous non-small cell) that has certain genetic changes. Participants must have already tried and failed a standard targeted therapy (TKI). The goal is to see if AK112 can shrink tumors …

This study looks at whether giving the numbing drug lidocaine during lung cancer surgery can lower the chance of the cancer returning or spreading. About 1,400 adults having minimally invasive lung cancer surgery will be randomly assigned to receive either lidocaine or a placebo …

This study tests a combination of two drugs, HLX43 and Serplulimab, in people with advanced lung cancer that has spread or cannot be removed by surgery. The goal is to find the right dose and see if the treatment shrinks tumors and is safe. About 120 adults aged 18 to 75 with non…

This study tests a combination of two drugs, chidamide and ivonescimab, in 32 adults with advanced non-small cell lung cancer that has stopped responding to immunotherapy and has a specific protein marker (high YAP). The goal is to see if the combo can shrink tumors or delay canc…

This study tests two treatment plans for people with lung cancer that has spread to the brain but isn't causing major symptoms. One group gets targeted radiation to all brain tumors first, then a drug combo (ivonescimab plus chemo). The other group gets the drug combo alone. The …

This study tests two experimental drugs together in people with advanced non-small cell lung cancer that has HER2 abnormalities. The drugs aim to shrink tumors and delay cancer growth. About 30 adults aged 18-75 who have not responded to prior therapy or are newly diagnosed will …

This study compares a new drug, YL202, with the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to previous treatments. About 440 adults aged 18 to 75 will take part. The main goals ar…

This study looks at whether giving a drug called Leucogen along with the cancer drug Pralsetinib can prevent low white blood cell counts in people with a specific type of advanced lung cancer (RET fusion-positive NSCLC). The study will involve 25 people who have not had prior tre…

This early-phase study tests whether combining izalontamab brengitecan with adagrasib can help people whose advanced KRAS G12C lung cancer keeps growing despite other treatments. About 18 adults will receive the drug pair to check safety and see if the combination works better th…

This study tests whether combining a targeted drug (furmonertinib) with local treatments like ablation or stereotactic radiation can help control early-stage non-small cell lung cancer in people who cannot have surgery or choose not to. About 45 participants with specific EGFR ge…

This study tests a new drug called JYP0322 against standard chemotherapy for people with a specific type of advanced lung cancer (ROS1-positive non-small cell lung cancer) that has stopped responding to earlier targeted treatments. About 207 participants will be randomly assigned…

This study tests whether adding a new drug (recaticimab) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with resectable non-small cell lung cancer. About 78 adults with stage II to IIIB cancer will receive the combination, then have surg…

This study looks at whether surgically removing the primary lung tumor before starting the targeted drug osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer live longer without the disease getting worse. About 118 adults with stage III-IV cancer who h…

This study looks at whether a 12-week exercise program can improve how well immunotherapy works in people with non-small cell lung cancer. One hundred participants will either do moderate or high-intensity interval cycling, or receive standard exercise advice. Researchers will me…

This early study tests a new radioactive drug called NTH-2403 in about 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The drug is designed to attach to a protein found on certain cancer cells and light them up on scans. The main goal i…

This study looks at whether low-dose CT scans can help find lung cancer early in people aged 40 to 80 who have never smoked. Researchers will also test a new risk prediction model using questionnaires, blood, urine, and lung function tests. The goal is to improve screening for no…

This study tests a LINE chatbot that provides visual, interactive tips to help lung cancer patients manage side effects from targeted therapy. About 178 people with advanced lung cancer will either get usual care or also access the chatbot. The goal is to see if the chatbot impro…

This study tests whether adding megestrol acetate (a drug that stimulates appetite) to standard first-line therapy helps malnourished non-small cell lung cancer patients gain weight. About 116 adults with advanced lung cancer will be randomly assigned to receive either standard t…

This pilot study will test whether a personalized exercise program is practical for 20 adults with stage II or III non-small cell lung cancer who have not yet started treatment. Participants will follow the Precise Exercise Regimen for Cancer Care (PERCC) program before beginning…

This study looks at whether a two-week program of walking and breathing exercises before surgery can help people with non-small cell lung cancer feel less pain, recover faster, and leave the hospital sooner. About 62 adults scheduled for lung cancer surgery will be split into two…

This study tests whether adding pentoxifylline and vitamin E to standard cancer treatment can prevent lung injury (pneumonitis) in 150 adults with stage III non-small cell lung cancer. Participants will receive the drugs alongside chemoradiation and immunotherapy. The goal is to …

This study tests a new way to perform robotic lung surgery for early-stage non-small cell lung cancer. Surgeons will use 3D virtual reality models and a special dye (ICG) that glows under near-infrared light to see exactly which part of the lung to remove. The goal is to make the…

This study will collect tumor samples from 150 adults with non-small cell lung cancer (stages I to IV) to learn why the cancer starts, grows, and sometimes returns. Researchers will analyze the samples for molecular, metabolic, and immune features, then link those findings to pat…

This early study tests a non-invasive device that sends low-intensity electric fields to lung tumors before surgery. The goal is to see how these fields affect certain genes in the cancer. 18 people with stage I-IIIA non-small cell lung cancer will take part. The main focus is sa…

This study interviews about 85 lung cancer patients and 15 doctors to learn what helps or hinders patients from continuing a targeted pill called osimertinib after surgery. The goal is to identify barriers like side effects, costs, or communication issues, and facilitators like s…

This study looks at whether a blood test can find tiny bits of cancer DNA left after surgery in people with breast, lung, prostate, ovarian, or stomach cancer. About 840 adults who had surgery to remove their cancer will give blood samples over 9 months. The goal is to see how of…

This study looks at whether tiny particles in the blood, called extracellular vesicles, can help doctors predict if immunotherapy will work for people with advanced lung cancer or melanoma. Researchers will collect blood samples from 378 patients before and during standard treatm…

This study compares two ways to plan lung cancer surgery: a standard CT scan with contrast dye versus a 3D model made from a CT scan without dye. Researchers want to see if the 3D model is just as accurate for finding tumors and mapping blood vessels. About 50 adults with early-s…

This study aims to find out if changes in specific immune cells in the blood can predict how well chemoimmunotherapy works in people with advanced non-small cell lung cancer. Researchers will collect blood samples from 80 participants before and after two treatment cycles. The go…

This early study looks at whether adding febuxostat (a gout medicine) to the standard lung cancer drug osimertinib can increase how much of the cancer drug gets into the brain fluid. Only 7 patients with EGFR-mutated lung cancer and no brain metastases will take part. The goal is…